Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Form 144 notice for Beta Bionics (BBNX) reports a proposed sale of 16,158 common shares through Merrill Lynch with an aggregate market value of $268,376.10. The filing lists 43,470,125 shares outstanding and an approximate sale date of 08/19/2025 on NASDAQ. The securities were acquired the same day (08/19/2025) via a stock option from Beta Bionics and payment is listed as cash. The filing also discloses a prior sale by Mark Hopman of 868 shares on 06/02/2025 for $15,529.00. The signer certifies they have no undisclosed material information and provides the standard Rule 10b5-1 and legal attestations.
This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.
The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.
Beta Bionics reports that Sands Capital Life Sciences Pulse Fund II, Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 3,570,113 shares of common stock, equal to 8.2% of the class based on 43,470,125 shares outstanding as reported July 25, 2025. The filing shows 0 shares of sole voting or dispositive power and 3,570,113 shares of shared voting and dispositive power. The reporting parties file jointly and certify the holdings were not acquired to change or influence control of the issuer.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have filed a Schedule 13G disclosing beneficial ownership of approximately 2.93 million Beta Bionics (BBNX) common shares, representing 6.8 % of the outstanding class as of 30 June 2025. All voting (2.93 m) and dispositive (2.93 m) rights are reported as shared; the firms hold no sole authority.
The filing was made under Rule 13d-1(b), signalling a passive investment. Morgan Stanley is classified as a parent holding company (HC), while the subsidiary is a broker-dealer (BD). The certification states the position was acquired in the ordinary course of business and not to influence control. A near-7 % institutional stake from a globally recognised financial institution may enhance BBNX’s liquidity, analyst coverage and investor credibility.
Beta Bionics, Inc. (Nasdaq: BBNX) filed an 8-K to disclose materials from its first Investor & Analyst Event held on 22 June 2025 in conjunction with the ADA Scientific Sessions. Exhibit 99.1 contains a detailed slide deck highlighting two-year, real-world performance of the iLet Bionic Pancreas.
The company analysed data from 16,439 commercial users who uploaded ≥3 weeks of CGM readings between 19 May 2023 and 18 May 2025. A core cohort of 14,952 users with baseline HbA1c records showed an average HbA1c reduction from 8.9 % to a GMI of 7.3 %. Across multiple sub-groups—MDI converts (8,802 users), competitive HCL converts (2,910 users), endocrinology vs. primary-care settings, and “fully-closed loop” users—similar improvements were observed, with ≥83 % of patients meeting ADA hypoglycaemia targets (<4 % time <70 mg/dL; <1 % time <54 mg/dL).
Algorithmic performance data from 30,077 device sessions indicate the system reaches a steady-state GMI of 7.4 % within two days of initiation, underscoring rapid optimisation.
Management emphasises the potential clinical benefit of iLet but cautions that the forward-looking statements are subject to regulatory, financing and market risks. No financial metrics, revenue guidance or earnings updates were provided, and the furnished information is not deemed “filed” under the Exchange Act.